Related Experiment Videos
Caspofungin acetate: an antifungal agent.
1New York Presbyterian-New York Weill Cornell Center, New York, USA.
Summary
Caspofungin acetate, an echinocandin antifungal, shows fungicidal activity against various fungi, including resistant Candida strains. It offers a favorable safety profile and potential for treating invasive fungal infections in immunocompromised patients.
Area of Science:
- Pharmacology and Therapeutics
- Mycology
- Infectious Diseases
Background:
- Caspofungin acetate is an echinocandin antifungal agent.
- It exhibits fungicidal activity against a broad spectrum of fungal pathogens, including Candida spp., Aspergillus spp., and Histoplasma spp.
- The drug is effective against both fluconazole-resistant and fluconazole-susceptible strains of Candida albicans.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of caspofungin acetate.
- To evaluate its potential role in treating invasive fungal infections.
Main Methods:
- Review of existing pharmacological and clinical data.
- Analysis of data from human and animal studies.
- Comparison of caspofungin acetate with amphotericin B in clinical trials.
Main Results:
- Caspofungin acetate inhibits 1,3-beta-D-glucan synthase, disrupting fungal cell wall integrity.
- It has an elimination half-life of 9-10 hours, suitable for once-daily dosing.
- Clinical trials showed higher response rates for Candida esophagitis compared to amphotericin B.
- Favorable response rates were observed in patients with refractory invasive aspergillosis.
- Caspofungin acetate demonstrated a better safety profile with fewer adverse effects than amphotericin B.
Conclusions:
- Caspofungin acetate is a fungicidal agent with broad-spectrum antifungal activity and a good safety profile.
- Further clinical trials and cost-effectiveness data are needed before formulary recommendation.
- It may be a valuable addition to hospital formularies, especially for immunocompromised populations.